PIK3CA and breast cancer: However, the differences in the analytical performance of NGS and RT-PCR, the selection of the most appropriate tissue sample (i.e., primary site vs. metastasis), and the stability of PIK3CA mutations over the course of the disease have not been well documented so far in breast cancer.